Investor Relations
HµREL® Corporation is privately held.
For information regarding the Company’s investor relations please contact:

Robert Freedman
Chief Executive Officer
by email at: rfreedman@hurelcorp.com
or by phone at: 310.652.5900.

HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD